ANDA 90293, held by Ph Health. Ethinyl Estradiol; Norethindrone Acetate.
As of Nov 16, 2026, ANDA 90293 (Gildess 24 Fe), held by Ph Health, was first approved by FDA on Dec 1, 2014, with 5 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 1, 2014 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Gildess 24 Fe0.02MG;1MG · tablet;oral | Ethinyl Estradiol; Norethindrone Acetate | Discontinued |
| Jul 8, 2025 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jul 8, 2025 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jul 8, 2025 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jul 8, 2025 | Supplement 5Labeling · Standard review | Approved | None posted |
| Jul 8, 2025 | Supplement 6Labeling · Standard review | Approved | None posted |
| Dec 1, 2014 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters